Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 7 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Insmed Incorporated has 7 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 6 examiners and 6 art units, showing broad distribution across examination personnel and technical groups.
NGUYEN, JOHN P is the busiest examiner, with 2 pending matters. Counsel can coordinate those matters where their issues overlap, but the wider portfolio still calls for application-level review.
Consistent claim terminology and technical support may improve prosecution efficiency across related cases. Examiner and art-unit differences make it important to adapt amendments and arguments rather than use a uniform response without review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 1 (12%) |
| §112 only | 1 (12%) |
| Double-patenting only | 2 (25%) |
| Multi-statute (no §101) | 3 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, JOHN P | 2 | 43.9% | +41.8% |
| HOLLOMAN, NANNETTE | 1 | 60.7% | +23.1% |
| MURESAN, ANA Z | 1 | 75.0% | +31.2% |
| AL-AWADI, DANAH J | 1 | 54.6% | +13.2% |
| RAGHU, GANAPATHIRAM | 1 | 73.7% | +26.5% |
| ONDACHI, PAULINE WANJIKU MUCH | 1 | 100.0% | +0.0% |
| WARD, AARON DUREL | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18787251 | DEIMMUNIZED LYSOSTAPHIN AND METHODS OF USE | RAGHU, GANAPATHIRAM | — |
| 18704872 | CERTAIN N-(1-CYAN0-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINOSINUSITIS | ONDACHI, PAULINE WANJIKU MUCH | — |
| 18294792 | ADENO-ASSOCIATED VIRUS PARTICLES AND METHODS OF USE THEREOF | WARD, AARON DUREL | — |
| 18513377 | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | NGUYEN, JOHN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19092890 | METHODS FOR CONTINUOUS MANUFACTURE OF LIPOSOMAL DRUG PRODUCTS | HOLLOMAN, NANNETTE | — |
| 19031214 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | MURESAN, ANA Z | — |
| 18974779 | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | AL-AWADI, DANAH J | — |
| 18787251 | DEIMMUNIZED LYSOSTAPHIN AND METHODS OF USE | RAGHU, GANAPATHIRAM | — |
| 18513377 | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | NGUYEN, JOHN P | — |
| 18034619 | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | NGUYEN, JOHN P | — |
| Art Unit | Apps |
|---|---|
| 1619 | 2 |
| 1612 | 1 |
| 1692 | 1 |
| 1615 | 1 |
| 1652 | 1 |
| 1627 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19092890 | METHODS FOR CONTINUOUS MANUFACTURE OF LIPOSOMAL DRUG PRODUCTS | HOLLOMAN, NANNETTE | 1612 | DP | Non-Final OA | — | Pending | Mar 27, 2025 |
| 19031214 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | MURESAN, ANA Z | 1692 | §112Other | Non-Final OA | — | Pending | Jan 17, 2025 |
| 18974779 | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | AL-AWADI, DANAH J | 1615 | DP | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18787251 | DEIMMUNIZED LYSOSTAPHIN AND METHODS OF USE | RAGHU, GANAPATHIRAM | 1652 | §101§102§103§112Other | Non-Final OA | — | Pending | Jul 29, 2024 |
| 18704872 | CERTAIN N-(1-CYAN0-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINOSINUSITIS | ONDACHI, PAULINE WANJIKU MUCH | 1627 | §103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18294792 | ADENO-ASSOCIATED VIRUS PARTICLES AND METHODS OF USE THEREOF | WARD, AARON DUREL | 1636 | §103§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18513377 | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | NGUYEN, JOHN P | 1619 | §103§112Other | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18034619 | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | NGUYEN, JOHN P | 1619 | §103 | Non-Final OA | — | Pending | Nov 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInsmed Incorporated has 8 pending office actions as of October 2026, spread across 7 art units and 7 examiners.
John P Nguyen has the most, with 2 of Insmed Incorporated's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
